Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Michael Mendler, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Michael Mendler, MD
Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 41 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bausch Health Americas, Inc.
- ID
- NCT01846663
- Phase
- Phase 4 research study
- Study Type
- Interventional
- Participants
- Expecting 100 study participants
- Last Updated